Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9386587 | 0.97 | PAOX (0.39) | PAOXMC4RSIGMAR1KDM4ETDP1 | |
| SCHEMBL10829091 | 0.87 | ALOX15 (0.44) | KDM4EALOX15 | |
| SCHEMBL8775141 | 0.87 | — | — | |
| SCHEMBL1673059 | 0.87 | ALOX15 (0.44) | KDM4EALOX15 | |
| SCHEMBL9277448 | 0.83 | PAOX (0.47) | PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL27923832 | 0.81 | PAOX (0.50) | PAOXSIGMAR1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6143515 | 0.81 | PAOX (0.46) | PAOXMC4RSIGMAR1ALOX15LMNA | |
| SCHEMBL40839 | 0.81 | PAOX (0.46) | PAOXMC4RSIGMAR1ALOX15LMNA | |
| SCHEMBL15183069 | 0.80 | SIGMAR1 (0.37) | SIGMAR1KDM4EGAAALOX15 | |
| SCHEMBL686085 | 0.80 | DRD2 (0.43) | SIGMAR1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823069-A | Inhibitor for improving rheumatoid arthritis by targeting C3aR1 and application thereof | 安徽省立医院(中国科学技术大学附属第一医院) | 2025-04-15 | — | — | CN | claimed |
| CN-103153329-A | Use of novel cyclosporin A derivatives for the treatment and prevention of viral infections | S & T GLOBAL INC | 2013-06-12 | — | — | CN | claimed |
| EP-0614664-B2 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | EP | claimed |
| EP-0614664-B1 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-09-16 | — | — | EP | claimed |
| US-5519024-A | CELL ADHESION INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-05-21 | — | — | US | claimed |
| US-5304647-A | Addition of an organolithium reagent; dehydrogenation of addition product; two-phase conditions prevents hydrolysis | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1994-04-19 | — | — | US | claimed |
| WO-1989011279-A1 | NUCLEIC ACID INTERACTING UNFUSED HETEROPOLYCYCLIC COMPOUNDS | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1989-11-30 | — | — | WO | claimed |
| WO-1989007599-A2 | NOVEL DIAZINES AND THEIR METHOD OF PREPARATION | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1989-08-24 | — | — | WO | claimed |
| CN-119823069-A | Inhibitor for improving rheumatoid arthritis by targeting C3aR1 and application thereof | 安徽省立医院(中国科学技术大学附属第一医院) | 2025-04-15 | — | — | CN | disclosed |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| EP-4219516-A2 | CHIRAL CONTROL | Wave Life Sciences Ltd. (SG) | 2023-08-02 | — | — | EP | disclosed |
| EP-4137572-A1 | CHIRAL DESIGN | Wave Life Sciences Ltd. (SG) | 2023-02-22 | — | — | EP | disclosed |
| EP-2872147-B1 | METHOD FOR MAKING CHIRAL OLIGONUCLEOTIDES | WAVE LIFE SCIENCES LTD (SG) | 2022-12-21 | — | — | EP | disclosed |
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-4590004-A | MICROBIOCIDES | RHONE-POULENC SANTE (FR) | 1986-05-20 | — | — | US | disclosed |
| EP-0074599-A1 | 5,6-cis-Carbapenem derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-03-23 | — | — | EP | disclosed |
| US-4278674-A | ANTIBACTERIAL ANTIBIOTICS | SANDOZ LTD. (CH) | 1981-07-14 | — | — | US | disclosed |
| US-4208326-A | ANTIBIOTICS | SANDOZ LTD. (CH) | 1980-06-17 | — | — | US | disclosed |
| US-4107164-A | ANTIBIOTICS, ANTIBACTERIAL | SANDOZ LTD. (CH) | 1978-08-15 | — | — | US | disclosed |
| US-4032530-A | ANTIBIOTICS | SANDOZ LTD. (CH) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | PAOX 3995/4885MC4R 679/4885SIGMAR1 4049/4885 |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | PAOX 1226/4885MC4R 1568/4885SIGMAR1 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.